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To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To obtain consensus on the
definition of APD, we performed a prospective, multicenter, Spanish nationwide, 3-round Delphi study (CEPA study). An ad hoc
questionnaire was designed with 33 questions concerning the relevance of several clinical features for APD diagnosis. In the first-
round, 240 neurologists of the SpanishMovementDisordersGroupparticipated in the study.The results obtainedwere incorporated
into the questionnaire and both, results and questionnaire, were sent out to and fulfilled by 26 experts in Movement Disorders.
Review of results from the second-round led to a classification of symptoms as indicative of “definitive,” “probable,” and “possible”
APD. This classification was confirmed by 149 previous participating neurologists in a third-round, where 92% completely or very
much agreed with the classification. Definitive symptoms of APD included disability requiring help for the activities of daily living,
presence of motor fluctuations with limitations to perform basic activities of daily living without help, severe dysphagia, recurrent
falls, and dementia. These results will help neurologists to identify some key factors in APD diagnosis, thus allowing users to
categorize the patients for a homogeneous recognition of this condition.
1. Introduction
Parkinson disease (PD) is the second most common age-
related neurodegenerative disorder after Alzheimer’s disease,
affecting nearly 1% of the population over 60 years and 5%
in subjects up to 85 years [1, 2], with high health, social, and
economic impact [3].
While currently effective antiparkinsonian drugs are
available, allowing patients to have an acceptable functional
capacity during the early years of PD, as time goes by,
motor and functional deterioration develop, partly due to
the presence of motor and nonmotor complications, highly
influencing patients’ quality of life. At this stage, the conven-
tional medication is unable to provide an adequate clinical
control [4–6] and the term advanced PD is frequently used
(APD).
However, the term APD is still controversial and is
variably applied to patients with long disease duration or
with motor fluctuations and severe or moderate dyskinesia,
with disorders of gait and equilibrium, or with cognitive
impairment or neuropsychiatric symptoms [4, 7, 8]. Many
of these symptoms do not improve with conventional ther-
apies, although for motor fluctuations and dyskinesias there
are alternative treatments, so-called “advanced therapies,”
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including deep brain stimulation (DBS), continuous sub-
cutaneous apomorphine infusion, or the infusion of lev-
odopa/carbidopa intestinal gel [9], to which the majority of
patients can have a satisfactory response. Therefore, it is of
interest to know the patients’ clinical characteristics that can
defineAPDand thatmake these patients eligible for advanced
therapies.
In this context, the primary objective of this study was to
reach a consensus on the definition of APDusing three round
questionnaires with Delphi methodology.
2. Methods
2.1. Study Design. This multicenter study was performed
using Delphi method [10–12]. The study protocol was
approved by the Ethics Committee of Hospital Cĺınic i
Provincial de Barcelona (Spain) in May 2013.
2.2. Scientific Committee. Five neurologists from 5 different
Spanish centers, experts in Movement Disorders and PD,
formed the Scientific Committee. After a careful review of
the literature [13], a questionnaire reflecting some of the
proposed features defining APD (clinical characteristics and
treatment) was created. The Scientific Committee validated
the methodology, study design, and study protocol and
prepared the questionnaire, analyzed the results of the two
first rounds, and added the statistical analysis from the first-
round to the second questionnaire. Based on the results of
the two rounds, the Scientific Committee elaborated a list of
clinical characteristics of APD, which was again sent to all
participants (third-round) to reach a final consensus.
2.3. Questionnaires. The first-round questionnaire included
a total of 33 items with a 0–4 scale: 0 (no determinant), 1
(little), 2 (some), 3 (sufficiently), and 4 (absolutely) (available
at http://cepa.medynet.com/).
The selected questions assessed the significance of 7
different factors in the diagnosis and definition of APD
(general characteristics of the disease, type and level of
disability, presence and severity of motor fluctuations and
dyskinesia induced by dopaminergic drugs, occurrence and
severity of motor and nonmotor symptoms related to the
disease, neuropsychiatric and cognitive manifestations, and
response of symptoms to available therapies). In the second-
round questionnaire, the results obtained in the first-round
questionnaire were incorporated.
2.4. Participant Groups. To obtain valid results, the Scientific
Committee estimated the minimum number of participants
as 150 neurologists in the first-round, 25 in the second-round,
and 125 in the third-round, to obtain a confidence level of
90% and a margin of error of ±5.35% in the first-round and a
confidence level of 95% and a margin of error of ±5% in the
third-round.
Participants included in the three rounds were neurolo-
gists attending more than 10 PD patients per year (66% of
participants attended more than 100 patients with PD/year)
and with professional activity in Spain. In the first-round,
neurologists of the Movement Disorders Group of the Span-
ish Society of Neurology were included, while, in the second-
round, neurologists with recognized expertise in PD (defined
as working in specialized Movement Disorder Units), who
also had participated in the first-round, were selected. Finally,
neurologists of the first-roundparticipated in the third-round
again.
2.5. Delphi Methodology. The study was performed using a
Delphi process, based on the anonymity for the individual
responses, controlled opinion feedback, and statistical anal-
ysis of responses.
After fulfilling the first-round questionnaires, statistical
analysis and conclusions were performed and incorporated
to the second-round questionnaires, the results of which led
to obtain the final conclusions, which were subsequently
confirmed and assessed by the third-round experts.
According to the Delphi methodology [14, 15], consensus
was established at percentages > 75% in one or two consecu-
tive scores. Hence, symptoms were classified as (1) definitive
for the diagnosis (considered as absolutely determinant by
>75% of participants); (2) probable (considered as sufficient
or absolute determinant by >75%); and (3) possible (con-
sidered as some, sufficiently, or absolutely determinant by
>75%).
In the third-round, participants were asked about their
level of agreement with the definition of APD, using the
scores: 0 (no determinant), 1 (little), 2 (some), 3 (sufficiently),
and 4 (absolutely).
2.6. Statistical Analysis. Results were expressed as a measure
of central tendency and dispersion for continuous variables
and as absolute numbers and relative frequencies for cate-
gorical variables. Comparisons in the clinical variables were
performed using a Student’s 𝑡-test or one-way ANOVA for
continuous variables (normality assumption was previously
confirmed) and Fisher exact test for categorical variables.
Statistical significance was set at 𝑝 < 0.05. The statistical
analysis was performed using SAS v.9.1.3 (SAS Institute Inc.,
USA).
The minimum sample size (𝑛 = 150) was representative
from the Spanish neurologists and was calculated to obtain
a sample error of 0.0535, considering a maximum variability
of 𝑃 = 𝑄 = 50% and a confidence interval of 90%. The
minimum sample size of the third-round (𝑛 = 125) was
calculated to obtain a sample error of 0.05 at a confidence
interval of 95%.
3. Results
3.1. Participants. The study was performed fromMay 2013 to
April 2014. A total of 240 Spanish neurologists participated
in the first-round and 26 in the second-round, and 149
neurologists of the first-round also participated in the third-
round.
During the first-round, a total of 240 questionnaires
were collected and 230 were considered valid (95.83%), from
the 10 nonvalid questionnaires, 4 were incomplete, and 6
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were completed by neurologists who attend less than 10 PD
patients per year. Participants of the second-round attended
more patients/year (65.38% attended >300 patients/year)
than the first-round participants (26.52% attended >300
patients/year).
3.2. Determinant Factors for APD
3.2.1. General Characteristics. The majority of participants
considered that disease duration was a determinant factor for
the diagnosis of APD (86.10% in first-round and 92.31% in
second-round considered it sufficiently or absolutely deter-
minant). Participants considered a mean disease duration of
9.17±1.95 years (median = 10.00 years) as determinant factor
for APD.
3.2.2. Disability. In both rounds all participants considered
that the type and level of disability were sufficiently (mean
score = 3) or absolutely decisive (mean score = 4) for the
diagnosis of APD. Second-round researchers considered that
a minimum level of disability was required to establish the
diagnosis of APD. 100% considered that patients have APD
“when the patient requires help for the activities of daily
living (such as communication, transportation, shopping,
grooming, eating, or medication management)” while for
73.08% the fact that the patient has limitations to perform
basic activities of daily living without help can be absolutely
determinant to establish the diagnosis of APD.
3.2.3. Motor Symptoms Related to Dopaminergic Treatment.
The presence of motor fluctuations was sufficiently or abso-
lutely decisive for the diagnosis of APD for 68.30% of partic-
ipants in the first-round and for 88.46% in the second-round
(Table 1). All participants of the second-round who were in
agreement with this statement (𝑛 = 23) also considered
that the duration of off periods when the best conventional
treatment has been prescribed was key for the diagnosis
of APD. In addition, they considered a mean percentage
of waking day in off situation of 24.13% ± 11.45 (median:
25.00%). “Any limitation to perform basic activities of daily
living, with preservation of autonomy,” and “requiring help
for the activities of daily living” were also considered by
78.26% and 100%, respectively, the required level of disability
during off periods.
88.70% of participants in the first-round and 76.92% in
the second-round considered that the functional disability
created by dyskinesia was sufficiently or absolutely crucial for
APD diagnosis (Table 1). In the second-round, participants
were asked to determine the mean percentage of daily on
hours with dyskinesias, reporting a mean of 28.25% of the
daily on hours with dyskinesia (median = 25.00%).
Those participants agreeing that functional disability
created by dyskinesia was sufficiently or absolutely important
for APD diagnosis also considered that the minimum level of
disability due to dyskinesia for APD diagnosis was “requiring
help for the activities of daily living” (100%) and “limitation
to perform basic activities, but the patient can perform them
without help” (90.00%).
3.2.4. Motor and Nonmotor Symptoms Related to the Disease.
For 87.80% of participants of the first-round the presence of
recurrent falls was sufficiently or absolutely decisive for APD
diagnosis (sufficiently: 47.40%; absolutely: 40.4%) and in the
second-round 100% of participants agreed (Table 1). Freezing
of gait was also considered a key factor for the diagnosis
for most neurologists both in first- (82.60%) and second-
round (96.15%) (Table 1). For 88.70% of neurologists in the
first-round and 92.31% of participants in the second-round,
alterations of postural reflexes and equilibrium were quite
or absolutely determinant (Table 1). Regarding dysphagia,
92.70% in the first-round and 88.46% in the second-round
considered the presence of moderate or severe dysphagia
suggestive (sufficiently and absolutely determinant) of APD
(Table 1). Moderate and/or severe dysarthria were considered
as indicative (sufficiently and absolutely determinant) of APD
for 77.40%of neurologists in the first-round and 76.92% in the
second-round. The term moderate or severe dysphagia and
dysarthria was defined in accordance with the UPDRS scale,
part II.
In the second-round, nonmotor symptoms related to
the disease such as symptomatic orthostatic hypotension
(76.90%), dysautonomia (77.80%), and excessive daytime
somnolence (69.20%) were some or sufficiently decisive in
APD diagnosis. Although these nonmotor symptoms can be
present in any stage of the disease, neurologists considered
that their severity was a feature of advanced stages.
3.2.5. Neuropsychiatric and Cognitive Disorders. Neuropsy-
chiatric and cognitive manifestations of the disease such
as moderate/severe depression, mild cognitive impairment,
chronic presence of hallucinations with preserved insight,
moderate/severe apathy, and impulse control disorders were
considered as possible features for APD diagnosis (Table 1).
In the second-round 57.70% of neurologists considered
moderate/severe depression as no or little determinant, 69.2%
established mild cognitive impairment as some, sufficiently,
or absolutely determinant, 80.80% considered hallucinations
with preserved insight as some, sufficiently (26.9%), or
absolutely determinant (50.0%), 34.60% agreed on moder-
ate/severe apathy as sufficiently or absolutely determinant,
and 42.20% of participants established the presence of
impulse control disorders as some, sufficiently, or absolutely
determinant for APD diagnosis (Table 1).
In the first-round dementia was considered sufficiently or
absolutely determinant for APD diagnosis by 91.30% (suffi-
ciently: 33.90%; absolutely: 57.40%) and by 96.15% of respon-
ders of the second-round. Hallucinations without insight
were also considered as sufficiently and absolutely decisive
by 83.50% of first-round respondents and by 92.31% in
second-round.The psychotic symptomswere also considered
decisive to some degree (some, sufficiently, and absolutely) by
91.8% and 92.31% of the first- and second-round respondents,
respectively (Table 1).
3.2.6. Symptoms as Indicative of APD. According to the
answers obtained in the second-round and in the experience
of the ScientificCommittee, the following PD symptomswere
4 Parkinson’s Disease















(A) Motor symptoms related to treatment
Motor fluctuations 68.30 88.46
Duration of off periods > 25% 89.50 100.00
Off disability 92.10 100.00 84.62
Limitation to perform
instrumental activities 47.83
Limitation to perform basic
activities (but without help) 78.26
Requiring help for daily living
activities 100.00
Durations of on dyskinesias > 25% 53.50
Functional disability due to
dyskinesias 88.70 76.92 76.92
Limitation to perform
instrumental activities 50.00
Limitation to perform basic
activities (but without help) 90.00
Requiring help for daily living
activities 100.00
(B) Motor symptoms related to the disease
Recurrent falls 87.80 100.00
Freezing of gait 82.60 96.15
Alteration of postural reflexes and
equilibrium 88.70 92.31
Moderate or severe dysphagia 92.70 88.46 76.92
Moderate or severe dysarthria 77.40 76.92
(C) Neuropsychiatric and cognitive disorders
Moderate/severe depression 20.50 57.50 15.40 42.30
Mild cognitive impairment 29.50 76.50 26.90 69.20
Dementia 91.30 97.00 96.15 92.31
Chronic presence of hallucinations
with preserved insight 39.50 83.80 50.00 80.80
Hallucinations without insight 83.50 95.70 92.31
Psychotic symptoms 73.50 91.80 92.31
Moderate/severe apathy 45.60 76.50 34.60 69.20
Impulse control disorders 29.10 65.20 38.40 42.20
considered for themselves as indicative of APD: dementia
(92.31%), disability requiring help for the activities of daily
living (88.46%), off disability (84.62%), moderate or severe
dysphagia (76.92%), functional disability due to dyskinesia
(76.92%), and autonomic dysfunction (53.85%) (Table 1).
3.2.7. Response of APD Symptoms to Available Therapies.
Regarding the degree of clinical benefit induced by different
therapies on PD symptoms, 53.50% of neurologists in the
first-round and 96.15% in the second-round considered that
moderate/severe axial symptoms (such as balance, speech,
and gait disturbances) had poor or no benefit from the
available therapies. Similarly, 94.3% and 92.31% of first-
and second-round respondents, respectively, also considered
that dementia does not improve or poorly responds to the
existing therapies. Nonmotor symptoms were considered to
have moderate or no response to the available therapies
by most respondents (89.10% and 92.31% in the first- and
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second-round, resp.). Most participants agreed that motor
fluctuations and dyskinesia significantly improve with cur-
rent therapies. In the first-round 91.80% of neurologists
established that motor fluctuations are markedly reduced
by available treatments while in the second-round the per-
centage reached 96.15%. Dyskinesia had moderate to excel-
lent response to available treatments for 99.20% first-round
respondents and 84.00% for second-round participants. In
summary, participants considered that motor fluctuations
and dyskinesia could improve with current therapies while
motor symptoms related to the disease and the majority of
nonmotor symptoms have a poor or absent response to the
existing therapies. Then, the lack of clinical benefit with the
available therapiesmight be considered as a factor in defining
APD.
3.2.8. Symptoms Classification and Final Definition. The
results of the three rounds allowed us to define 3 different
categories of PD symptoms that can help to define APD:
definitive symptoms, probable symptoms, and possible symp-
toms. The symptoms were grouped in 6 different areas (gen-
eral characteristics of the disease, disability, motor symptoms
related to the treatment, motor symptoms related to the
disease, nonmotor symptoms related to the disease, and
neuropsychiatric and cognitive manifestations).
Definitive symptoms were considered those whose pres-
ence, even isolated, was enough to classify PD as APD.These
included disability requiring help for the activities of daily
living, presence of motor fluctuations with limitations to
perform basic activities of daily living without help, severe
dysphagia, recurrent falls, and dementia (Table 2).
Probable symptoms indicative of APD included time
of evolution of the disease (around 10 years), limitation to
perform basic activities of daily living, even if not requiring
help, functional disability due to dyskinesia that covered
more than 25% of waking day, moderate dysphagia, freezing
of gait, moderate or severe dysarthria, and hallucinations
without preserved insight (Table 2). The association of two
probable symptoms of different areas made them a definite
symptom.
Finally, possible symptoms included postural and balance
impairment, symptomatic dysautonomia (including symp-
tomatic orthostatic hypotension), and excessive daytime
somnolence, moderate or severe apathy, chronic presence of
hallucinations with preserved insight, psychotic symptoms,
andmild cognitive impairment (Table 2).The combination of
one possible “motor or nonmotor symptom related with the
disease” areas with one possible symptom of the “neuropsy-
chiatric and cognitive” area made them a probable symptom.
This classification of symptoms was confirmed by the
majority of the neurologists of the third-round (92.00%
were in complete or quite agreement), while a minority of
participants was in slight (7.38%) or poor agreement (0.67%).
Therefore, based on these results, APD can be defined as
an advanced stage of PD in which certain symptoms and
complications are present, with a detrimental influence on the
overall patient’s health conditions and with a poor response
to conventional treatments (Table 2).
4. Discussion
Current evidence suggests that both motor and nonmotor
symptoms significantly contribute to health status and quality
of life in PD [8].
A progressive limitation for carrying out the usual activi-
ties of daily living (disability) with disease progression is very
common in PD. Such limitation results from a combination
of motor impairment and complications, but also from
nonmotor symptoms that can restrict the activity through
a diversity of ways (fatigue, apathy, cognitive impairment,
pain, etc.) and aging [16, 17]. As the disability increases,
patients require to be helped for carrying out basic activities
of daily living and, finally, are totally dependent of caring by
others, leading to a great negative impact on patients and
caregivers life [18]. Therefore, disability must be considered
a fundamental feature for grading PD stage, although other
characteristics as the disease duration, usually longer than
10 years, or the incapacity to obtain enough clinical benefit
from conventional therapies are also important in defining
APD.
Today, however, there is no agreement among neurolo-
gists concerning the clinical features that PD should exhibit
to be considered as APD [4, 5].
Using the Delphi methodology in a large sample of
neurologists we have obtained a consensus on the definition
and clinical characteristics that PD patients exhibit in the
advanced stage of PD. Most importantly, we have been able
here to describe some definitive symptoms of PD that, when
present, are sufficient to classify patients as having APD.
In addition, this study has allowed us to identify certain
symptoms that, when combined, could allow identifying
possible and probable APD patients.
We found that bothmotor and nonmotor symptomswere
definitive for the diagnosis of APD, either related to the
evolution of the disease or related to the long-term levodopa
therapy. In fact, the appearance of certain intrinsic motor
symptoms of PD, as recurrent falls and severe dysphagia
were definitive determinants for the diagnosis of APD, while
moderate dysphagia and freezing of gait were probable symp-
toms for APD diagnosis. Classically, these manifestations
have been associated with advanced disease and, frequently,
parallel the appearance of cognitive decline [19, 20].
The development of severe motor fluctuations with dis-
abling “off” periods was also considered a definitive factor
for APD diagnosis. These motor complications can appear
early in the course of the disease, particularly in young
patients, and rethought to reflect the extent of nigrostriatal
degeneration. These motor manifestations can dramatically
improve with currently available therapies like DBS, contin-
uous subcutaneous apomorphine infusion, or the infusion of
levodopa/carbidopa intestinal gel.
Accordingly, we can suggest that APD would be reached
when the underlying pathological substrate of PD is
widespread but also when PD patients develop the char-
acteristic complications associated with long-term levodopa
treatment [20, 21]. In both instances the common feature
is the impact they have on disability and quality of life.




























































































































































































































































































































































































































































































































































































































































disease or by long-term levodopa therapy was considered
for 100% of participants as a definitive factor for APD
diagnosis.
Neuropsychiatric manifestations are common in both
nondemented and demented PD patients [22]. Most partic-
ipants established that dementia and hallucinations without
insight are, respectively, definitive andprobable symptoms for
APD diagnosis. This is consistent with studies showing that
more than 80%of PDpatients develop dementia after 20 years
of the disease evolution and also with reports describing that
hallucinations are probably the clinical symptom most con-
sistently associated with progressive cognitive deterioration
and dementia in PD [23].
The number and severity of the nonmotor symptoms, as
a whole, increase with PD progression, although in a variable
manner [24–26]. Nonetheless, in late stages of the disease, the
nonmotor symptoms may be the dominant problem in many
patients [27] and have a huge impact on patient’s health state,
quality of life, and instrumental functionality [28–30].
Finally, in order to assess the real impact of this consensus
in clinical practice we should now evaluate whether or not
the 3 different categories of symptoms (definitive, probable,
and possible) ascribed to APD clearly classify PD patients in
different stages of the disease in the clinical practice.
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